Report for: Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Title	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Published in	BMC Cancer, July 2010
DOI	10.1186/1471-2407-10-368
Pubmed ID	20630061
Authors	Milind M Javle, Rachna T Shroff, Henry Xiong, Gauri A Varadhachary, David Fogelman, Shrikanth A Reddy, Darren Davis, Yujian Zhang, Robert A Wolff, James L Abbruzzese
Abstract	The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies suggest that prolonged exposure of pancreatic cancer cells to mTOR inhibitors can promote insulin receptor substrate-PI3K interactions and paradoxically increase Akt phosphorylation and cyclin D1 expression in pancreatic cancer cells (negative feedback loop). The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models.

View on publisher site Alert me about new mentions

Mendeley readers

The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Netherlands	1	<1%
Australia	1	<1%
United Kingdom	1	<1%
Japan	1	<1%
United States	1	<1%
Unknown	128	96%

Demographic breakdown

Readers by professional status	Count	As %
Student > Ph. D. Student	25	19%
Researcher	22	17%
Unspecified	12	9%
Student > Master	11	8%
Student > Bachelor	9	7%
Other	32	24%
Unknown	22	17%

Readers by discipline	Count	As %
Medicine and Dentistry	42	32%
Agricultural and Biological Sciences	15	11%
Biochemistry, Genetics and Molecular Biology	12	9%
Unspecified	12	9%
Nursing and Health Professions	8	6%
Other	15	11%
Unknown	29	22%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2019.

All research outputs

#3,617,248

of 22,759,618 outputs

Outputs from BMC Cancer

#834

of 8,277 outputs

Outputs of similar age

#15,242

of 94,825 outputs

Outputs of similar age from BMC Cancer

of 57 outputs

Altmetric has tracked 22,759,618 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 8,277 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 89% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 94,825 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.

We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

About this Attention Score

Mentioned by

Citations

Readers on

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context